Organization, Liquidity and Basis of Presentation - Additional Information (Detail) $ / shares in Units, $ in Thousands				3 Months Ended
	Jul. 25, 2024 USD ($) shares	Jul. 22, 2024 USD ($) $ / shares shares	Jul. 12, 2024	Mar. 31, 2025 USD ($)	Mar. 31, 2024 USD ($)	Dec. 31, 2024 USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Date of incorporation				Feb. 14, 2019
Retained earnings accumulated deficit				$ (266,995)		$ (246,684)
Cash flow from used in operating activities				(19,841)	$ (15,086)
Cash, cash equivalents and investments				166,000
Cumulative gross proceeds from convertible notes derivative instruments and redeemable convertible preferred stock				401,700
Redeemable convertible preferred stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stockholders equity stock split			0.2057
IPO [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Sale of stock issue price per share | $ / shares		$ 12
Proceeds from initial public offer	$ 162,300	$ 167,000
Stock issued during the period shares new issues | shares		13,920,000
Payment of stock issuance costs		$ 15,900
Sale of stock net consideration received on the transaction		$ 151,100
Over-allotment option [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from initial public offer	$ 12,000
Stock issued during the period shares new issues | shares	1,000,000
Proceeds from issuance of common stock	$ 11,200
Commissions	$ 800
Common Stock [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Stockholders equity stock split			0.2057
Merck exclusive license and collaboration agreement [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Receipt from the counterparty				$ 39,900